PolTREG S.A. received information on November 21, 2022 that the company’s project entitled “Cell therapy of prediabetes based on artificially multiplied CD4+CD25+CD127- regulatory lymphocytes and antiCD20 antibody” has been qualified for funding from the Medical Research Agency. The total cost of the project is PLN 49.5 million. The grant awarded to the company is PLN 31.7 million, while the project’s implementation period is scheduled for 2022-2028. The condition for the transfer of funds is the signing of a grant agreement. The aim of the project is to conduct Phase II clinical trials.
2022-11-21
PolTREG S.A recommended to receive PLN 31.7 million grant from the Medical Research Agency to conduct Phase II clinical trials in cell therapy for prediabetes conditions
See other news
2025-01-20
PolTREG secures PLN 51.4M grant recommendation from Polish Agency for Enterprise Development for groundbreaking multiple sclerosis therapy
2025-01-09
PolTREG obtains Japanese patent for intrathecal PTG-007 therapy in multiple sclerosis
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
